Clinical Trial Update: Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC [Phase 2]

View source ↗

Summary

Phase II trial update from Shanghai Henlius Biotech evaluating HLX07 + serplulimab + chemotherapy versus placebo + serplulimab + chemotherapy as first-line trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Chemotherapy (unspecified regimen)
• HLX07 (HLX07)
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Nasopharyngeal Carcinoma by AJCC V8 Stage | Phase 2 | Status: ACTIVE_NOT_RECRUITING